BACKGROUND: Despite the increasing use of palliative chemotherapy for advanced colorectal cancer, there remains uncertainty as to the true effectiveness of this intervention. This review was therefore undertaken to assess the available evidence for the benefit of palliative chemotherapy in this disease. OBJECTIVES: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer. A secondary objective was to investigate outcomes for younger and elderly patients. SEARCH STRATEGY: Trials were identified by computerised and hand searches of the literature, scanning references and contacting investigators. SELECTION CRITERIA: All randomised controlled trials of palliative chemotherapy compared with supportive care alone in patients with advanced or metastatic colorectal cancer. Both randomised and non-randomised studies were considered when searching for data on quality of life, resource use and cost effectiveness of palliative chemotherapy. DATA COLLECTION AND ANALYSIS: Investigators from all eligible studies were asked to supply individual patient data. Meta-analysis was performed using both published data and individual patient data. Studies were grouped according to whether chemotherapy was administered regionally or systemically. MAIN RESULTS: 13 randomised controlled trials representing a total of 1365 randomised patients met the inclusion criteria. Meta-analysis of a subset of trials that provided individual patient data demonstrated that palliative chemotherapy was associated with a 35% (95% CI 24% to 44%) reduction in the risk of death. This translates into an absolute improvement in survival of 16% at both 6 months and 12 months and an improvement in median survival of 3.7 months. The overall quality of evidence relating to treatment toxicity, symptom control and quality of life was poor. REVIEWER'S CONCLUSIONS: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated by this meta-analysis, as a proportion of patients in the control arms of some trials received chemotherapy. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. Treatment toxicity and impact upon quality of life and symptom control have been inadequately assessed in the majority of trials and further research is needed to clarify the palliative benefit of chemotherapy.
BACKGROUND: Despite the increasing use of palliative chemotherapy for advanced colorectal cancer, there remains uncertainty as to the true effectiveness of this intervention. This review was therefore undertaken to assess the available evidence for the benefit of palliative chemotherapy in this disease. OBJECTIVES: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer. A secondary objective was to investigate outcomes for younger and elderly patients. SEARCH STRATEGY: Trials were identified by computerised and hand searches of the literature, scanning references and contacting investigators. SELECTION CRITERIA: All randomised controlled trials of palliative chemotherapy compared with supportive care alone in patients with advanced or metastatic colorectal cancer. Both randomised and non-randomised studies were considered when searching for data on quality of life, resource use and cost effectiveness of palliative chemotherapy. DATA COLLECTION AND ANALYSIS: Investigators from all eligible studies were asked to supply individual patient data. Meta-analysis was performed using both published data and individual patient data. Studies were grouped according to whether chemotherapy was administered regionally or systemically. MAIN RESULTS: 13 randomised controlled trials representing a total of 1365 randomised patients met the inclusion criteria. Meta-analysis of a subset of trials that provided individual patient data demonstrated that palliative chemotherapy was associated with a 35% (95% CI 24% to 44%) reduction in the risk of death. This translates into an absolute improvement in survival of 16% at both 6 months and 12 months and an improvement in median survival of 3.7 months. The overall quality of evidence relating to treatment toxicity, symptom control and quality of life was poor. REVIEWER'S CONCLUSIONS: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated by this meta-analysis, as a proportion of patients in the control arms of some trials received chemotherapy. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. Treatment toxicity and impact upon quality of life and symptom control have been inadequately assessed in the majority of trials and further research is needed to clarify the palliative benefit of chemotherapy.
Authors: J F Smyth; J D Hardcastle; G Denton; D Alderson; R H Grace; J L Mansi; H M Yosef; O Nordle; H Lauri; S Wählby Journal: Ann Oncol Date: 1995-11 Impact factor: 32.976
Authors: A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: A Gerard; M Buyse; J C Pector; H Bleiberg; J P Arnaud; G Willems; G Delvaux; M Lise; D Nitti; G Depadt Journal: Eur J Surg Oncol Date: 1991-06 Impact factor: 4.424
Authors: D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: Marco Ravanelli; Giorgio Maria Agazzi; Elena Tononcelli; Elisa Roca; Paolo Cabassa; Gianluca Baiocchi; Alfredo Berruti; Roberto Maroldi; Davide Farina Journal: Radiol Med Date: 2019-06-06 Impact factor: 3.469
Authors: M W van den Berg; M Ledeboer; M G W Dijkgraaf; P Fockens; F ter Borg; J E van Hooft Journal: Surg Endosc Date: 2014-10-08 Impact factor: 4.584
Authors: Simone Mocellin; Zora Baretta; Marta Roqué I Figuls; Ivan Solà; Marta Martin-Richard; Sara Hallum; Xavier Bonfill Cosp Journal: Cochrane Database Syst Rev Date: 2017-01-27
Authors: Yoon Mi Shin; Hae Suk Han; Seong Woo Lim; Byung Chul Kim; Kyung Suck Cheoi; Young Ook Eum; Seung Taek Kim; Ki Hyeong Lee Journal: Cancer Res Treat Date: 2005-10-31 Impact factor: 4.679